Teleflex Inc (TFX): Stuart A Randle , director of Teleflex Inc sold 797 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $166.10 per share for a total value of $132,377.72 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on May 18, 2016, Thomas Anthony Kennedy (Senior VP, Global Operations) sold 15,102 shares at $160.20 per share price.On Aug 21, 2015, Patricia C Barron (director) sold 1,500 shares at $132.74 per share price.Also, On May 29, 2015, William Roland Cook (director) sold 8,000 shares at $128.89 per share price.On Mar 9, 2015, Stuart A Randle (director) sold 870 shares at $121.78 per share price.
Shares of Teleflex Incorporated (TFX) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.46 points or -0.28% at $165.72 with 2,64,397 shares getting traded. Post opening the session at $166.15, the shares hit an intraday low of $165.0401 and an intraday high of $166.85 and the price vacillated in this range throughout the day. The company has a market cap of $7,225 M and the number of outstanding shares has been calculated to be 4,35,95,541 shares. The 52-week high of Teleflex Incorporated is $166.85 and the 52-week low is $122.13.
Company has been under the radar of several Street Analysts.Teleflex Incorporated is Reiterated by Barclays to Overweight and the brokerage firm has raised the Price Target to $ 170 from a previous price target of $155 .The Rating was issued on Apr 29, 2016.
Teleflex Incorporated is a provider of medical technology products. The Company designs develops manufactures and supplies single-use medical devices used by hospitals and healthcare providers for diagnostic and therapeutic procedures in critical care and surgical applications. The Company also markets and sells its products to hospitals and healthcare providers. The Company operates its business in six segments: Vascular North America; Anesthesia/Respiratory North America; Surgical North America; Europe the Middle East and Africa (EMEA); Asia and Original Equipment Manufacturer (OEM). The Company manufactures its products at 26 manufacturing sites with manufacturing operations located in the Czech Republic Germany Malaysia Mexico and the United States. The Companys specialty product line consists of a range of catheters including Foley intermittent external and suprapubic; urine collectors; catheterization accessories and products for operative endourology.